Busey Bank Acquires 20,423 Shares of Pfizer Inc. $PFE

Busey Bank grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 653,112 shares of the biopharmaceutical company’s stock after purchasing an additional 20,423 shares during the quarter. Busey Bank’s holdings in Pfizer were worth $16,263,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. YANKCOM Partnership purchased a new position in Pfizer during the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the 3rd quarter valued at about $29,000. Darwin Wealth Management LLC purchased a new position in Pfizer during the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC grew its holdings in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1%

Shares of NYSE PFE opened at $27.58 on Monday. Pfizer Inc. has a 12 month low of $21.87 and a 12 month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $156.83 billion, a price-to-earnings ratio of 20.28 and a beta of 0.43. The business has a 50-day moving average of $27.27 and a 200-day moving average of $26.05.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Pfizer’s revenue was down 1.2% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on PFE shares. Royal Bank Of Canada started coverage on Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.45.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.